63 KB157 KB47 KB192920262006Čebular, BoštjanZgonc, Vidštevilka:6/7letnik:75str. 379-388ISSN:1318-0347COBISSID:21523417URN:URN:NBN:SI:doc-AHZRSZ5NslSlovensko zdravniško društvoZdravniški vestnikAdministration And DosageAnticonvulsantsAntikonvulziviBlooddrugDrug TherapyepilepijaEpilepsijaEpilepsyPharmacologytherapyzdravilazdravljenjeSodobno medikamentno zdravljenje epilepsije pri odraslih| Modern medicamentous treatment of epilepsy in adults|Background Several newer antiepileptic drugs (AEDs), i. e. vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin and zonisamide have been introduced into clinicalpractice within the lastdecade. Most of these new drugs are atleast as effective as the older"AEDs (phenobarbital, phenytoin, valproic acid, carbamazepine) and in general, they seem to be better tolerated then the older drugs and have less side effects. The development of pharmaceutical industry has brought several new AEDs to clinical practice which increased a probability of therapeutic success, but also made treatment more complex. It is expected from the physician that she will know indications and contraindications for at least ISAEDs, their optimal titration, dosage, possible side effects and wide spectrum of interactions with other drugs. At this point advertisements of drug companies try to convince us aggressively about success of their own products. Conclusion This review article focuses on modern medicamentous treatment of adults with epilepsy, main characteristics of newer AEDs, conditionsm availability and statistics of their usage in SloveniaIzhodišča V zadnjih 10 letih so se v klinični praksi uveljavila številna novejša protiepileptična zdravila (PEZ), kot so vigabatrin, lamotrigin, gabapentin, topiramat, tiagabin, okskarbazepin, levetiracetam, pregabalin in zonisamid. Večinoma so vsaj tako učinkovita kot starejša PEZ (fenobarbital, fenitoin, valproat, karbamazepin), le da jih bolniki veliko bolje prenašajo inimajo manj neželenih učinkov. Razvoj farmacevtske industrije je prinesel številna novejša PEZ, ki so povečala verjetnost terapevtskega uspeha, a tudi povečala zapletenost zdravljenja. Od zdravnika se pričakuje, da bo poznal indikacije in kontraindikacijeza vsaj 15 PEZ, njihovo optimalno titracijo, odmerjanje, možne neželene učinke in širok spekter interakcij z drugimi zdravili. Pri tem nas marketinški oglasi proizvajalcev zdravil vse siloviteje prepričujejo o uspešnosti prav njihovih izdelkov. Zaključki Nastal je pregledni članek, ki govori o sodobnem medikamentnem zdravljenju odraslih z epilepsijo, stanju in dostopnosti novejših PEZ v Sloveniji, njihovih glavnih značilnostih in statistiki uporabe v SlovenijiTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo